Silverback Therapeutics (SBTX) Stock Analysis

What Silverback Therapeutics does

Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immune response through the precise activation of TLR8 within the liver. The company was founded in 2016 and maintains its principal offices in Seattle, Washington.

Key metrics

ETFs linked to SBTX

Broad-market and Healthcare sector ETFs an investor holding Silverback Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SBTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Silverback Therapeutics?

Silverback Therapeutics trades under the ticker SBTX on NASDAQ.

Which exchange is SBTX listed on?

SBTX is listed on NASDAQ.

What sector does Silverback Therapeutics operate in?

Silverback Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SBTX in a portfolio?

PortView shows SBTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.